Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke

PHASE4RecruitingINTERVENTIONAL
Enrollment

580

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

May 31, 2027

Conditions
Mild Stroke
Interventions
DRUG

Tirofiban+Oral Dual Antiplatelet Therapy

Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 47.5 hours; sequential Oral Dual Antiplatelet Therapy (Aspirin 100mg qd; Clopidogrel 75mg qd)

DRUG

Oral Dual Antiplatelet Therapy

Aspirin 100mg qd; Clopidogrel 75mg qd (after first dose of 300mg)

Trial Locations (18)

215004

RECRUITING

Second Affiliated Hospital of Soochow University, Suzhou

Unknown

RECRUITING

Suzhou Municipal Hospital of Anhui Province, Suzhou

RECRUITING

Second Hospital of Hebei Medical University, Shijiazhuang

RECRUITING

Taikang Xian People's Hospital, Zhoukou

RECRUITING

WuYuan County People's Hospital, Bayan Nur

RECRUITING

Huai'an First People's Hospital, Huai'an

RECRUITING

Jiangsu Province (Suqian) Hospital, Suqian

RECRUITING

Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou

RECRUITING

Changshu No.1 People's Hospital, Suzhou

RECRUITING

First People's Hospital of Kunshan, Suzhou

RECRUITING

Suzhou Ninth People's Hospital, Suzhou

RECRUITING

Suzhou Xiangcheng People's Hospital, Suzhou

RECRUITING

Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou

RECRUITING

Zhangjiagang Hospital of Traditional Chinese Medicine, Suzhou

RECRUITING

Taixing Second People's Hospital, Taizhou

RECRUITING

Nuclear Industry 417 Hospital, Xi'an

RECRUITING

First People's Hospital of Xianyang, Xianyang

RECRUITING

Second Hospital of Tianjin Medical University, Tianjin

All Listed Sponsors
lead

Second Affiliated Hospital of Soochow University

OTHER